Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07618390 | A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. | not yet recruiting | Phase 2 | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT07619066 | A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.(AGATHA) | not yet recruiting | Phase 2 | 25 | MedSIR |
| 0 |
| Jun 1, 2026 |
| clinicaltrials |
| NCT07610525 | Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial | not yet recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610733 | Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.(IFOCOS) | not yet recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 0 | May 28, 2026 | clinicaltrials |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer(SPECTACLE) | not yet recruiting | Phase 2 | 140 | Fudan UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07285993 | Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET | not yet recruiting | Phase 2 | 15 | Randy YehOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07539753 | Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases | not yet recruiting | Phase 2 | 46 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 286 | AkesoINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer(JAZMINE) | not yet recruiting | Phase 1 / Phase 2 | 24 | MedSIROTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07015853 | ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | not yet recruiting | Phase 2 | 34 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07527806 | Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging | not yet recruiting | Phase 2 | 156 | Peking University Cancer Hospital & InstituteOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT07528898 | Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. | not yet recruiting | Phase 2 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02802423 | Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | not yet recruiting | Phase 1 / Phase 2 | 44 | BioLite, Inc.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07509515 | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. | not yet recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07499999 | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer(BabyTEARS) | not yet recruiting | Phase 2 | 140 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 84 | Xijing HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer(EPPIL) | not yet recruiting | Phase 2 | 760 | Institut Jean-GodinotOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07428018 | Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib(VIOLET) | not yet recruiting | Phase 2 | 150 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07441486 | A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT07423611 | ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer(RACE) | not yet recruiting | Phase 2 | 388 | Fudan UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07419867 | A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI | not yet recruiting | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07410559 | Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | not yet recruiting | Phase 2 | 189 | Fudan UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416253 | Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer | not yet recruiting | Phase 2 | 68 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07417241 | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | not yet recruiting | Phase 2 | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07410169 | Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy | not yet recruiting | Phase 2 / Phase 3 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410234 | Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT07406789 | Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).(LUMInova) | not yet recruiting | Phase 2 | 100 | TNC Nutrición Terapéutica S.L.OTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07370506 | Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 36 | Tanta UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07367178 | Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer(SATROPIN) | not yet recruiting | Phase 2 | 30 | MedSIROTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07368543 | Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer(STORM) | not yet recruiting | Phase 2 | 216 | Fudan UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07353437 | Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) | not yet recruiting | Phase 2 | 334 | Fudan UniversityOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07336771 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 60 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07307287 | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07305246 | Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer | not yet recruiting | Phase 2 | 120 | First Hospital of China Medical UniversityOTHER | 0 | Dec 26, 2025 | clinicaltrials |
| NCT07299409 | First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. | not yet recruiting | Phase 2 | 24 | Nathalie LevasseurOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299890 | An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | not yet recruiting | Phase 2 | 90 | Anhui Provincial Cancer HospitalOTHER | 0 | Dec 23, 2025 | clinicaltrials |
| NCT07300215 | An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Dec 23, 2025 | clinicaltrials |
| NCT07290166 | A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.(Cinderella-Neo) | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 0 | Dec 18, 2025 | clinicaltrials |
| NCT07292142 | FMT in Triple Negative Breast Cancer Guided by ctDNA(FRIDA) | not yet recruiting | Phase 1 / Phase 2 | 125 | Jewish General HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07292207 | Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer(ARCHE) | not yet recruiting | Phase 2 | 30 | Nagoya City UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05128734 | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07271992 | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer(TREND-02) | not yet recruiting | Phase 2 | 30 | First Hospital of China Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07255612 | Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) | not yet recruiting | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | not yet recruiting | Phase 2 | 188 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07243418 | Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study | not yet recruiting | Phase 2 | 72 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 21, 2025 | clinicaltrials |
| NCT07178938 | Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases(THERANOVA) | not yet recruiting | Phase 2 | 10 | MedSIROTHER | 0 | Nov 14, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2026source: clinicaltrials